anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The SARS-CoV-2 pandemic continues to grow, with over 350,000 new infections and over 7,000 daily global deaths in May 2021 (WHO, 2021a). The current supplies of protective vaccines are too low to cover the worldwide demand hence researchers globally are urgently looking for interventions to prevent new infections, prevent disease progression, and lessen disease severity for those already infected. According to data released by the ministry of health, Uganda had 94,904 confirmed cases with 2752 deaths at the end of July 2021 (MoH, 2021). Fortunately, most of the cases confirmed had a mild illness for whom home-based symptomatic management with monitoring of clinical deterioration as per World Health Organization recommendations is sufficing (WHO, 2021b). However, despite providing symptomatic management, a therapeutic drug that would limit infection is greatly needed to stop COVID-19 disease progression. While a number of claims on efficacy of herbal remedies on COVID-19 have been made, to our knowledge none of such claims have gained on scientific basis for continued use or further research and development of the constituents into investigational products.

COVIDEX is a herbal formulation containing berberine as a primary anti-SARSCOV-2 compound notified by the Uganda National Drug Authority for supportive treatment in managing viral infections. Notably, this notification was done with a call for clinical trials to validate the claims of its anti-SARS COV-2 activity. This study therefore proposes to investigate the safety and efficacy of COVIDEXTm therapy in managing COVID-19 disease.
PROBLEM TO BE SOLVED: To provide an elastic molding device for producing a molding having the surface brightness and precision of a molding having a holder like a lipstick. SOLUTION: This molding device consists of the holder of the molding, an elastic mold 1 and a mold parting cup enclosing the elastic mold 1. The holder 10 is a cylindrical body which has an injection port 11 for injecting a fluid molding material at the upper end and is formed with an open end on the lower side. The elastic mold 1 is formed as a bag-shaped body having the connecting part and collar part of the holder 10 in the aperture. The outside surfaces in the collar part and front end of the elastic mold 1 are provided with projecting parts 4, 7 or recessed parts. The mold parting cup is provided with recessed parts 8, 9 or projecting parts fitting to the projecting parts or the recessed parts of the elastic mold on the upper part or the bottom surface and has a suction port 6 for pressure reduction. The holder, the elastic mold 1 and the mold parting cup are so arranged that their respective central lines exist on the same line.
Provided are adenoviral vectors for generating an immune response to antigen.  The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.
The Neuroimmunology Branch (NIB) conducts research into the cause of immunologically mediated diseases of the nervous system such as multiple sclerosis (MS). The studies in the NIB range for studies of the natural history of MS to trials of new experimental therapies. In order to recruit patients into the various NIB research studies, patients with a tentative diagnosis are initially seen by the NIB to assess the accuracy of the diagnosis and to assess the level of disease activity occurring in the patient. Patients seen under the NIB screening protocol are evaluated in clinic with a complete neurological examination. Blood studies necessary to eliminate the possibility of many other causes of disease that may resemble MS are performed. Spinal fluid examination may be preformed if uncertainty exists with respect to the diagnosis. Finally, patients will have at least one MRI preformed to assess the consistency with MRI findings expected in MS. Most patients will have a series of three MRIs done approximately one month apart in order to assess the frequency of new contrast enhancing lesions occurring in the patient. The level of disease on MRI is important both from the standpoint of diagnosis as well as determining if the patient may be eligible for any other NIB protocols. To assess the patient's eligibility for other NIB studies, the NIB may periodically follow patients in whom the diagnosis is uncertain or in whom the level of disease activity is not clear for the initial evaluation.
FIELD: medicine, immunology. SUBSTANCE: invention relates to an immunocorrecting agent and a method of immunocorrection in treatment of patients with different diseases accompanying disorders of immune system functions. Immunocorrecting agent is a proteoselenium complex including a low-molecular organic component obtained from the protein-containing raw by extraction with alcohol or ether, or dimexide followed by extract drying and its dissolving in 60-90% alcohol and selenium ionized an organic salt as measured 3-6 mcg/ml of solution. The mixture is kept in the electromagnetic sinusoidal high-frequency field at frequency 20-30 MHz. Method of immunocorrection involves the administration of the proteoselenium complex at the daily dose 6-150 mg. Invention shows effectiveness in different pathological processes, provides energetic stimulation of cells, realizes the normalization of the function of the microcirculating alveus that results to the recovery of human body tissues natural structure and an adequate metabolic energetic processes. EFFECT: enhanced effectiveness of an agent. 15 cl, 1 tbl, 2 ex
A method for the modification of melanin distribution, and the composition thereof to modify melanin distribution are disclosed. A method for the reduction of melanin distribution, and the composition thereof to reduce melanin distribution are disclosed. A representative composition comprises 4-ethoxybenzaldehyde and one or more additional active agents as well as a pharmaceutically acceptable carrier or excipient. Carriers and excipients may be formulated for topical administration. Compositions may also be formulated for transdermal administration. The compositions may be used for the prevention and treatment of pigmentation disorders, by way of non-limited example, post-inflammatory hyperpigmentation and others. The compositions may be used for lightening skin.
The present invention relates to a method for providing personalized health lifestyle information by means of artificial intelligence based on the lifelog of a user in order to induce or maintain the appropriate weight of the user, and more specifically, to a method for managing the weight of the user. The present invention relates to a method for providing a lifestyle by means of artificial intelligence to induce or maintain the adequate weight of each individual user. In particular, the specific lifestyle pattern, which is more realistic, more precise, and more practicable, is provided with respect to the weight of the user by means of the lifelog data of the user. The present invention is provided by means of the user service application, the lifelog database, and the health management service server. To this end, the present invention is characterized by comprising: a lifelog data analysis step (S10); a weight state determination step (S20); and a personalized health lifestyle information providing step (S30) which provides lifestyle pattern information which induces the underweight to the normal weight depending on the weight state of the user, provides lifestyle pattern information which induces the obesity to the overweight when the weight state of the user is obese, provides lifestyle pattern information which induces the overweight to the normal weight when the weight state of the user is overweight, and provides lifestyle pattern information which may maintain the normal weight when the weight state of the user is normal. Therefore, the present invention provides the health lifestyle information composed of lifestyle patterns which can be maintained based on the lifestyle pattern of the user, such that the weight of the user may be effectively and practically maintained.
Esophageal cancer (EC) has a higher morbidity and mortality rate than most human malignancies. The standard treatment for unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is concurrent chemoradiotherapy, but survival remains limited. Carrilizumab combined with chemotherapy has been shown to have an excellent pathological remission rate in the treatment of advanced esophageal cancer and locally advanced esophageal cancer. Here, the investigators conducted a phase II, prospective, two-arm clinical study to explore the efficacy of Camrelizumab combined with chemotherapy versus chemoradiotherapy for conversion therapy in potentially resectable advanced esophageal squamous cell carcinoma. All participants meeting the inclusion criteria will be registered after signing the informed consent form. Patients with thoracic esophageal cancer with clinical staging of T4a and T4b or at least one group of lymph nodes likely to invade surrounding organs or with concomitant enlarged lymph nodes unresectable will be included in the study. According to the study plan, patients who completed two cycles of chemotherapy combined with Camrelizumab induction or concurrent chemoradiotherapy were randomly assigned to receive radical surgery after being assessed as operable. The primary endpoint was R0 removal rate in patients undergoing surgery after treatment. Secondary endpoints were major pathological response (MPR) rate, overall survival (OS), progression-free survival (PFS), and adverse events. This study will provide more evidence for the conversion treatment of initially unresectable locally advanced esophageal squamous cell carcinoma and contribute to the development of treatment guidelines for esophageal cancer.
The invention provides injection rifampicin and a preparing method thereof. The injection rifampicin comprises a rifampicin body and antioxidants. The antioxidants are sodium thiosulfate or sodium sulfite and preferentially are the sodium sulfite. The appearance color and luster of the injection rifampicin and the solution solubility in the preparing process are improved by adding excipients. A proper amount of PH adjustment agents are added, the PH is adjusted to range from 8.5 to 8.8, and the solution stability in the preparing process can be remarkably improved. The preparing method of the injection rifampicin includes the steps of solution preparing, carburization and decarburization filtering, sterilization filtering, filling plugging and freeze drying.
Of the 400 obese and non-obese adult asthmatics in New York City and Denver during the 18-month observational phase of this study, the study team will randomize 80 participants (40 in NYC and 40 in Denver) into a 4-week group session pilot study focused on beliefs and behaviors associated with asthma and obesity self-management behaviors (SMB). Eligibility will be determined based on Asthma Control Questionnaire (ACQ) score and body mass index (BMI) at their 12-month visit. Participants will be randomized into an intervention or an active control arm after completing their 18-month visit. Participants will be consented into the pilot study during or after their 18-month visit. Participants will be put into groups of 7-10 for the pilot. Once formed, groups will have four 1-hour weekly visits. A person will be allowed to make up one missed session. The make-up session will be conducted on the phone or in-person depending on scheduling availability of both participant and care coach. Participants will be given accelerometers at sessions 1 and 4 that they will be asked to wear for seven days and return along with an activity diary. A follow-up survey will be administered about 30 days after the last pilot session in order to reassess the patient's asthma, obesity, exercise and medication beliefs and their adherence to asthma SMB. At the time of the follow-up survey, participants will also be given accelerometers that they will be asked to wear for seven days and return along with an activity diary.
The experimental group of 36 patients underwent proximal massage and fist clenching after IV insertion. Proximal massage: For a total of 5 to 10 minutes, twice daily for 4 days, between 30 seconds- 1 minute in sessions of approximately 20 strokes, a light massage is administered utilizing the palm surfaces of the fingers. Fist Clenching : Under the researcher's supervision, participants in the activity known as palm fisting squeeze a soft palm ball 20 times in each of twice a day for four days, lasting between 30 seconds - 1 minute. The Peripheral Venous Catheter-Related Phlebitis Risk Scale, the Phlebitis Diagnostic Scale, and the Patient Information Form were employed right after following PVC (0. hour). The Phlebitis Diagnostic Scale was used for 96 hours to assess the patient's vascular access at the 24th, 48th, 72nd, and 96th hours.
1. Before treatment with gonadotropins is instituted, a thorough gynecologic and endocrinologic evaluation must be performed. This should include an assessment of pelvic anatomy. Patients with tubal obstruction should receive Ovidrel® PreFilled Syringe only if enrolled in an in vitro fertilization program.
  2. Primary ovarian failure should be excluded by the determination of gonadotropin levels.
  3. Appropriate evaluation should be performed to exclude pregnancy.
  4. Patients in later reproductive life have a greater predisposition to endometrial carcinoma as well as a higher incidence of anovulatory disorders. A thorough diagnostic evaluation should always be performed in patients who demonstrate abnormal uterine bleeding or other signs of endometrial abnormalities before starting FSH and Ovidrel® PreFilled Syringe therapy.
  5. Evaluation of the partner's fertility potential should be included in the initial evaluation.
The invention discloses a cyclic polypeptide and application thereof in preparing antitumor drugs. The amino acid sequence of the cyclic polypeptide is as follows: CKGKFKRPPLKRVRMSADAMLC. The invention also provides a preparation method of the cyclic polypeptide: the DNA sequence for encoding the cyclic polypeptide is cloned into a prokaryotic expression vector in a traceless way, then escherichia coli DH5 alpha is transformed, the expression is induced by IPTG, and then the label is removed by SUMO protease treatment, so that the cyclic polypeptide is obtained. The prepared cyclic polypeptide has improved enzymolysis stability and longer half-life, i.e. longer retention time in vivo. The invention also discovers through experiments that the cyclic polypeptide can inhibit the growth and proliferation of various tumor cells, so that the cyclic polypeptide can be used for resisting tumors.
An isolated polynucleotide encoding human Death Domain Containing  Receptor 5 (DR5) comprising a first nucleic acid that is at least 90% identical to a second nucleic acid selected from SEQ ID NO:2.  The amino acid sequences for the complete polypeptide and the mature polypeptide encoded by the cDNA clone are contained in ATCC Deposit No. 97920.  Also described is a vector, a host cell and a pharmaceutical composition comprising the polypeptide.  Disclosed is the use of polypeptide in the preparation of a medicament for the treatment of cancer, inflammation; autoimmune disease, viral infection, and graft vs. host disease.  The translated polypeptide is a member of the TNF family of receptors.  It binds TNF-related apoptosis-inducing ligand (TRAIL).  Methods for producing a vector containing the polynucleotide, translating the polypeptide using a host cell, using the host cell to screen for ligand binding to polypeptide, identifying agonists and antagonists of the polypeptide, the production of antibody using the polypeptide, and the diagnosis of disease or susceptibility to disease related to underexpression of the polypeptide are disclosed.
Ray tracing hardware accelerators supporting multiple specifiers for controlling the traversal of a ray tracing acceleration data structure are disclosed. For example, traversal efficiency and complex ray tracing effects can be achieved by specifying traversals through such data structures using both programmable ray operations and explicit node masking. The explicit node masking utilizes dedicated fields in the ray and in nodes of the acceleration data structure to control traversals. Ray operations, however, are programmable per ray using opcodes and additional parameters to control traversals. Traversal efficiency is improved by enabling more aggressive culling of parts of the data structure based on the combination of explicit node masking and programmable ray operations. More complex ray tracing effects are enabled by providing for dynamic selection of nodes based on individual ray characteristics.
Since 1993 The RGRM Method is a concept launched in both health and medical care. The method is mainly designed to help people with injuries and diseases of the central nervous system.
Ovarian cancer is diagnosed at advanced stages in 80% of cases, leading to 5-year survival of approximately 30 %. Tumor reductive surgery and platinum and taxane-based chemotherapy has been the mainstay of treatment for advanced disease . The presence of residual disease after primary debulking surgery is a highly significant prognostic factor in women with advanced ovarian cancer. In up to 60 % of women, residual tumor of \>1 cm is left behind after primary debulking surgery. These women might have benefited from neoadjuvant chemotherapy (NACT) prior to interval debulking surgery instead of primary debulking surgery followed by chemotherapy. Previous studies have demonstrated a clear survival benefit if resection to no gross residual disease (R0 resection) can be achieved, More extensive surgical procedures have been performed to achieve R0 status and have been associated with increased surgical morbidity. Accurate assessment of tumor burden at initial diagnosis using preoperative computed tomography, serum CA 125, and clinical factors has been used in models with variable success and has been difficult to standardize across surgical practices. It is important to determine at the time of diagnosis which patients should undergo primary tumor reductive surgery (TRS), and which should receive neoadjuvant chemotherapy (NACT) in order to minimize surgical morbidity and maximize the extent of cytoreduction. As such, several algorithms to predict the extent of disease encountered at cytoreductive surgery have been developed and evaluated . Fagotti et al. (2008) developed a laparoscopic scoring algorithm comprised of seven parameters: omental caking, peritoneal carcinomatosis, diaphragmatic carcinomatosis, mesenteric retraction, bowel infiltration, stomach infiltration, and liver metastases. . A laparoscopy-based scoring model developed by Fagotti et al.,(2008) demonstrated that a predictive index value score of 8 or greater had a specificity of 100%, positive predictive value of 100%, and negative predictive value of 70% for predicting a suboptimal primary tumor reductive surgery. Optimal tumor reductive surgery was defined as

1 cm or less in this model . Follow-up studies have demonstrated that laparoscopic scoring carries a low risk of complications; helps avoid unnecessary laparotomies in patients in whom cytoreduction to no gross residual disease would not be possible. To provide a more standardized approach to the management of patients with advanced ovarian cancer, this study will be performed to triage appropriate patients to laparoscopic scoring assessment using the previously validated scoring algorithm as reported by Fagotti, We will estimate the effects of the laparoscopic scoring algorithm in patients with advanced ovarian cancer to improve complete gross surgical resection rates and to determine the resulting clinical outcomes.
On the day of surgery, all patients (Group A and Group B) will receive a multi-modal oral pre-operative cocktail and an ultrasound guided adductor canal block. Additionally, an ultrasound guided popliteal or infiltration of the tissue plane between the popliteal artery and the capsule of the knee (iPACK) block will be administered. The pre-operative oral medication cocktail and block medications are as follows: Acetaminophen 975 mg x 1, Celecoxib 400 mg PO x 1, adductor canal block with 133 mg (10 mL) liposomal bupivacaine (EXPAREL) admixed with 0.5% bupivacaine HCl 50 mg (10 mL), popliteal or iPACK nerve infiltration with 133 mg (10 mL) liposomal bupivacaine (EXPAREL) admixed with 0.5% bupivacaine HCl 50 mg (10 mL). 15 mg IV ketorolac at conclusion of the case will be administered.
Cytokine storm syndromes (CSSs) are caused by a dysregulated host immune response to an inciting systemic inflammatory trigger. This maladaptive and harmful immune response culminates in collateral damage to host tissues resulting in life-threatening multisystem organ failure. Knowledge of the various immune cells that contribute to CSS pathogenesis has improved dramatically in the past decade. Monocytes, dendritic cells, and macrophages, collective known as monocytic phagocytes, are well-positioned within the immune system hierarchy to make key contributions to the initiation, propagation, and amplification of the hyperinflammatory response in CSS. The plasticity of monocytic phagocytes also makes them prime candidates for mediating immunoregulatory and tissue-healing functions in patients who recover from cytokine storm-mediated immunopathology. Therefore, approaches to manipulate the myriad functions of monocytic phagocytes may improve the clinical outcome of CSS.
ABSTRACT     The present invention relates to pro-hormone convertases and polypeptidic fragments thereof, nucleic acids encoding them,  recombinant viruses expressing these convertases, polyclonal antibodies directed against the convertases, diagnostic kits for the detection and measurement of the convertase content in cell or tissue lysates, culture media or biological fluids by RIA.   Diagnostic kits were also developped for detection or measurement of nucleic acids, preferably  mRNAs,   in  cell  or  tissue  lysates  by hybridization.        The    invention    also    concerns oligonucleotides useful as probes or as primers for DNA synthesis.   These oligonucleotides were included in the diagnostic kits as well as used for the obtention of specific fragments of the convertases which have served, together with native convertases,  as antigens  for the obtention of antibodies.  The convertases were produced by mammalian  cell  lines  transfected with the  recombinant viruses and purified on affinity columns which are also an object of the invention.   Processes for producing the native convertases, fragments thereof and antibodies are also described and claimed.
Patients receive dinaciclib IV over 2 hours on day 1 and epirubicin hydrochloride IV over 30 minutes on day 2. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.